Compare Citius Pharmaceuticals Inc (CTXR) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Krispy Kreme Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Krispy Kreme Inc trades at $3.1 (market cap $544.79M). The key difference: Krispy Kreme Inc is far larger — about 29.1× Citius Pharmaceuticals Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | DNUT | |
|---|---|---|
Market Cap | $18.73M | $544.79M |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $4.70 |
52-Week Low | $0.48 | $2.92 |
Enterprise Value | $14.95M | $1.79B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Krispy Kreme (DNUT) trades at $3.34, up 3.41% today, with a bullish technical signal from oscillators and mixed earnings history. The company reported a net loss of -$515.77M in 2025 but shows margin improvement and a capital-light refranchising strategy. Recent news highlights a turnaround focus, with the CEO affirming progress on profitability and leverage reduction.
Outlook hinges on execution of the turnaround plan; opportunities include international expansion and cost controls, but risks persist from high debt and competitive pressures. Analysts are cautiously optimistic with a 50% buy rating, though negative profitability metrics warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
